Brian Porter
Research Subjects
Research Interests
Brian Porter has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Helena Marzo-Ortega
NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UNITED KINGDOM
2 shared publicationsNicole Williams
Patient-Centered Outcomes Assessment, RTI Health Solutions, Durham, NC, USA
2 shared publicationsSteffen Jugl
Immunology and Dermatology, Novartis Pharma AG, Basel, SWITZERLAND
2 shared publications- Vibeke Strand
Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, USA
2 shared publications - Anna Halliday
Novartis Pharmaceuticals UK Limited Surrey UK
1 shared publication - Atul Deodhar
Oregon Health & Science University Portland
1 shared publication
Latest Publications
- Open Access
- 3 September 2019
- Published by AVES YAYINCILIK A.Ş. in European Journal of Rheumatology
- Vol. 5 (4) , 216-223
Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison
Objective: Matching-adjusted indirect comparison was used to assess the comparative effectiveness of secukinumab 150 mg and adalimumab 40 mg in biologic-naïve patients with ankylosing spondylitis (AS) for up to 1 year. Methods: Pooled individual patient data from the secukinumab arms of MEASURE 1 (NCT01358175) and MEASURE 2 (NCT01649375) trials (n=197) were matched against the ATLAS (NCT00085644) adalimumab population (n=208). Logistic regression analysis was used to determined weights to match for age, sex, Bath AS Functional Index, C-reactive protein levels, and previous tumor necrosis factor inhibitor therapy. Recalculated Assessment of SpondyloArthritis International Society (ASAS) 20 and 40 responses at weeks 8, 12, 16, 24, and 52 from MEASURE 1/2 (effective sample size=120) were compared with those of ATLAS. Anchored (placebo-adjusted) comparisons were possible until week 12, and unanchored (non-placebo- adjusted) comparisons were necessary thereafter. Results: For placebo-anchored ASAS 20 and 40 comparisons up to week 12, there were no differences between secukinumab and adalimumab. For unanchored comparisons at week 16, ASAS 20 was higher for secukinumab [odds ratio 1.60 (95% confidence interval, 1.01-2.54); p=0.047]; at week 24, ASAS 20 and 40 were higher for secukinumab [1.76 (1.11-2.79); p=0.017 and 1.79 (1.14-2.82); p=0.012, respectively]; and at week 52, ASAS 40 was higher for secukinumab [1.54 (1.06-2.23); p=0.023] than for adalimumab. Conclusion: There were no differences observed in placebo-adjusted ASAS 20 and 40 responses up to 12 weeks between secukinumab- and adalimumab-treated patients with ankylosing spondylitis. After week 12, secukinumab demonstrated signs of greater improvement in non-placebo-adjusted ASAS 20 and 40 responses than adalimumab. Cite this article as: Maksymowych WP, Strand V, Nash P, Yazici Y, Thom H, Hunger M, et al. Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison. Eur J Rheumatol 2018; 5: 216-23.
- 3 September 2019
- Published by AVES YAYINCILIK A.Ş. in European Journal of Rheumatology
- Vol. 5 (4) , 216-223
Open AccessComparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison
Objective: Matching-adjusted indirect comparison was used to assess the comparative effectiveness of secukinumab 150 mg and adalimumab 40 mg in biologic-naïve patients with ankylosing spondylitis (AS) for up to 1 year. Methods: Pooled individual patient data from the secukinumab arms of MEASURE 1 (NCT01358175) and MEASURE 2 (NCT01649375) trials (n=197) were matched against the ATLAS (NCT00085644) adalimumab population (n=208). Logistic regression analysis was used to determined weights to match for age, sex, Bath AS Functional Index, C-reactive protein levels, and previous tumor necrosis factor inhibitor therapy. Recalculated Assessment of SpondyloArthritis International Society (ASAS) 20 and 40 responses at weeks 8, 12, 16, 24, and 52 from MEASURE 1/2 (effective sample size=120) were compared with those of ATLAS. Anchored (placebo-adjusted) comparisons were possible until week 12, and unanchored (non-placebo- adjusted) comparisons were necessary thereafter. Results: For placebo-anchored ASAS 20 and 40 comparisons up to week 12, there were no differences between secukinumab and adalimumab. For unanchored comparisons at week 16, ASAS 20 was higher for secukinumab [odds ratio 1.60 (95% confidence interval, 1.01-2.54); p=0.047]; at week 24, ASAS 20 and 40 were higher for secukinumab [1.76 (1.11-2.79); p=0.017 and 1.79 (1.14-2.82); p=0.012, respectively]; and at week 52, ASAS 40 was higher for secukinumab [1.54 (1.06-2.23); p=0.023] than for adalimumab. Conclusion: There were no differences observed in placebo-adjusted ASAS 20 and 40 responses up to 12 weeks between secukinumab- and adalimumab-treated patients with ankylosing spondylitis. After week 12, secukinumab demonstrated signs of greater improvement in non-placebo-adjusted ASAS 20 and 40 responses than adalimumab. Cite this article as: Maksymowych WP, Strand V, Nash P, Yazici Y, Thom H, Hunger M, et al. Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison. Eur J Rheumatol 2018; 5: 216-23.
- 1 April 2018
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 57 (suppl_3)
176 Secukinumab provides sustained reduction in fatigue in patients with ankylosing spondylitis through three years: long-term results of two randomised double-blind placebo-controlled phase III studies
Background: Fatigue is common in patients with ankylosing spondylitis (AS) and negatively impacts social functioning and quality of life. We assessed the long-term effects of secukinumab on fatigue in TNF inhibitor (TNFi)-naive and TNFi inadequate responder/intolerant (TNFi-IR) AS patients in MEASURE 1 and MEASURE 2.
- 1 April 2018
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 57 (suppl_3)
176 Secukinumab provides sustained reduction in fatigue in patients with ankylosing spondylitis through three years: long-term results of two randomised double-blind placebo-controlled phase III studies
Background: Fatigue is common in patients with ankylosing spondylitis (AS) and negatively impacts social functioning and quality of life. We assessed the long-term effects of secukinumab on fatigue in TNF inhibitor (TNFi)-naive and TNFi inadequate responder/intolerant (TNFi-IR) AS patients in MEASURE 1 and MEASURE 2.
- Open Access
- 21 April 2017
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 56 (suppl_2)
107. LONG-TERM EFFICACY OF SECUKINUMAB CONDITIONAL ON RESPONSE STATUS AT WEEK 12: ANALYSIS IN TUMOUR NECROSIS FACTOR α INHIBITOR–NAÏVE AND TUMOUR NECROSIS FACTOR α INHIBITOR INADEQUATE RESPONDER PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS
Background: Ankylosing spondylitis (AS) is a chronic arthritic disease associated with pain and functional deterioration. Patients with active AS and an inadequate response to conventional therapy can be treated with several licensed biologic agents including tumour necrosis factor α (TNF-α) inhibitors and secukinumab, a first-in-class, fully human interleukin-17A inhibitor. However, treatment guidelines highlight the importance of assessing response to biologics after 12 weeks and only continuing treatment if there is clear evidence of response. Secukinumab has been demonstrated to significantly improve the signs and symptoms of AS in two randomized controlled trials, MEASURE 1 and MEASURE 2. This analysis aimed to assess the importance of response status at 12 weeks as an indicator of longer-term outcomes with secukinumab 150 mg in TNF-α inhibitor–naïve and TNF-α inhibitor inadequate responder (TNF-α inhibitor-IR; primary or secondary treatment failure, contraindications or intolerance).
- 21 April 2017
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 56 (suppl_2)
Open Access107. LONG-TERM EFFICACY OF SECUKINUMAB CONDITIONAL ON RESPONSE STATUS AT WEEK 12: ANALYSIS IN TUMOUR NECROSIS FACTOR α INHIBITOR–NAÏVE AND TUMOUR NECROSIS FACTOR α INHIBITOR INADEQUATE RESPONDER PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS
Background: Ankylosing spondylitis (AS) is a chronic arthritic disease associated with pain and functional deterioration. Patients with active AS and an inadequate response to conventional therapy can be treated with several licensed biologic agents including tumour necrosis factor α (TNF-α) inhibitors and secukinumab, a first-in-class, fully human interleukin-17A inhibitor. However, treatment guidelines highlight the importance of assessing response to biologics after 12 weeks and only continuing treatment if there is clear evidence of response. Secukinumab has been demonstrated to significantly improve the signs and symptoms of AS in two randomized controlled trials, MEASURE 1 and MEASURE 2. This analysis aimed to assess the importance of response status at 12 weeks as an indicator of longer-term outcomes with secukinumab 150 mg in TNF-α inhibitor–naïve and TNF-α inhibitor inadequate responder (TNF-α inhibitor-IR; primary or secondary treatment failure, contraindications or intolerance).